

Investigational Medicinal Product	Phase 1	Phase 2	Phase 3	Disease Area of Research
Tislelizumab (anti-PD-1)	[Red bar]			R/R cHL
	[Dark blue bar]			R/R cHL
BGB-10188 +/- Zanubrutinib	[Light blue bar]			B-cell malignancies
BGB-11417 (Bcl-2 inhibitor) monotherapy	[Red bar]			B-cell malignancies
	[Red bar]			R/R CLL/SLL
	[Red bar]			R/R MCL
BGB-11417 + Azacitidine +/- Posaconazole	[Dark blue bar]			Myeloid malignancies
BGB-11417 + Dexamethasone +/- Carfilzomib	[Dark blue bar]			R/R multiple myeloma with t(11;14)
BGB-11417 monotherapy + Zanubrutinib	[Dark blue bar]			B-cell malignancies
BGB-16673 (BTK-targeted CDAC)	[Yellow bar]			B-cell malignancies
	[Red bar]			B-cell malignancies
Ociperlimab (anti-TIGIT) +/- Tislelizumab or Rituximab	[Red bar]			R/R DLBCL
Zandelisib +/- Zanubrutinib or Rituximab*	[Purple bar]			CLL/SLL and B-cell NHL
Zanubrutinib	[Dark blue bar]			R/R CLL/SLL
	[Red bar]			CD79B R/R DLBCL
	[Light blue bar]			Previously treated B-cell malignancies
	[Pink bar]			B-cell malignancies
	[Dark blue bar]			Bioavailability of zanubrutinib tablets vs capsules in healthy volunteers [†]
Zanubrutinib + Lenalidomide +/- Rituximab	[Red bar]			R/R DLBCL
Zanubrutinib + Obinutuzumab	[Dark blue bar]			R/R FL
Zanubrutinib + Rituximab	[Dark blue bar]			1L MCL
	[Dark blue bar]			R/R MZL
Zanubrutinib +/- Venetoclax [†]	[Dark blue bar]			1L CLL/SLL

*In collaboration with MEI Pharma.

[†]This combination is being studied in the third cohort of NCT03336333.

Safety and efficacy have not been established for investigational products and/or uses.

CDAC, chimeric degradation activating compound; cHL, classical Hodgkin lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; PIK3δ, phosphoinositide 3-kinase delta; R/R, recurrent/refractory; TIGIT: T-cell immunoreceptor with Ig and ITIM domains; WM, Waldenström macroglobulinemia.

